Organic compounds -- part of the class 532-570 series – Organic compounds – Cyclopentanohydrophenanthrene ring system containing
Reexamination Certificate
2005-08-22
2009-10-13
Davis, Zinna N (Department: 1625)
Organic compounds -- part of the class 532-570 series
Organic compounds
Cyclopentanohydrophenanthrene ring system containing
Reexamination Certificate
active
07601857
ABSTRACT:
This invention relates to a process for the preparation of 6-hydroxyequilenins, which are useful as estrogenic agents.
REFERENCES:
patent: 6956126 (2005-10-01), Megati et al.
patent: 2003/0166627 (2003-09-01), Harris et al.
patent: WO 01/68669 (2001-09-01), None
Sakac et al, 1998, Journal of the Serbian Chemical Society, 63(1), pp. 21-24.
International Search Report and Written Opinion, PCT/US06/032590, Jan. 24, 2007, 9 pages.
Koppl, A. et al., “Heterogeneous Metallocene Catalysts For Ethylene Polymerization”, Journal of Molecular Catalysis, vol. 165, 2001, pp. 23-32.
Mendelsohn and Karas, “The protective effects of estrogen on the cardiovascular system,”New Engl. J. Med., 1999, vol. 340, 1801-1811.
Epperson, et al., “Gonadal steroids treatment of mood disorders,”Psychsomatic Med., 1999, vol. 61, 676-697.
Crandall, J. , “Estrogen replacement therapy and colon cancer: a clinical review,”Women's Health Gender-Based Med., 1999, vol. 8: 1155-1166.
Monk and Brodaty, “Use of estrogens for the prevention and treatment of Alzheimer's disease,”Dementia&Geriatric Cognitive Disorders, 2000, vol. 11, 1-10.
Hurn and Macrae, “Estrogen as a neuroprotectant in stroke,”J. Cerebral Blood Flow&Metab., 2000, vol. 20, 631-652.
Calvin, “Oestrogens and wound healing,”Maturitas, 2000, vol. 34, 195-200.
Finking, et al., “The effects of estrogen in the cardiovascular system,”Zeitshrift fur Kardiologie, 2000, vol. 89, 442-453.
Brincat, “Hormone replacement therapy and the skin,”Maturitas, 2000, vol. 35, 107-117.
Al-Azzawi, “The menopause and its treatment in perspective,”Postgrad Med. J., 2001, vol. 77, 292-304.
Moggs and Orphanides, “Estrogen receptors: orchestrators of pleiotropic cellular response,”EMBO Reports, 2001, vol. 2, 775-781.
Hall, et al., “The multifaceted mechanisms of estradiol and estrogen receptor signaling,”J. Biol. Chem., 2001, vol. 276, 36869-36872.
McDonnell, “The mechanism of action of steroid hormone receptors,” in Principles of Molecular Regulation, (2000) pp. 351-361.
McKenna, et al., “Nuclear receptor coregulators: cellular and molecular biology,” Endocrine Rev. (1999) 20:321-344.
Quaedackers, et al., “4-Hydroxytamoxifen trans-represses nucear factor kappa-B activity in human osteobastic U2-OS cells through estrogen receptor (ER)alpha and not through ERbeta,” Endocrinol. (2001) 142:1156-1166.
Bhat, et al., “A novel estrogen receptor beta: identification and functional analysis of additional N-termainal amino acids,” J. Steroid Biochem. Mol. Biol. (1998) 67:233-240.
Pelzer, et al., “Estrogen effects in the myocardium: inhibition of NF-kappaB DNA binding by estrogen receptor-alpha and -beta,” Biochem. Biophys. Res. Comm. (2001) 286:1153-1157.
Levin, “Cell localization, physiology, and non-genomic actions of estrogen receptors,” J. Appl. Physiol. (2001) 91:1860-1867.
Levin, “Cellular functions fo the plasma membrane estrogen receptor,” Trends Endocrinol. Metab. (1999) 10:374-377.
Green, et al., “Human oestrogen reseptor cDNA: sequence, expression and homology to v-erb-A,” Nature (1986) 320:134-139.
Kuiper, et al., “Cloning of a novel estrogen receptor expressed in rat prostate and ovary,” Proc. Natl. Acad. Sci. USA (1996) 93:5925-5930.
Couse, et al., “Tissue distribution and quantitative analysis of estrogen receptor-alpha (ERalpha) and estrogen receptor-beta (ERbeta) messenger ribonucleic acid in the wild-type and ERalpha-knockout mouse,” Endocrinol. (1997) 138:4613-4621.
Kuiper et al., “Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta,” Endocrinol. (1997) 138:863-870.
Sar and Welsch, “Differential expression of estrogen receptor-beta and estrogen receptor -alpha in the rat ovary,” Endocrinol. (1999) 140:963-971.
Fitzpatrick, et al., “Expression of estrogen receptor-beta protein in rodent ovary,” Endocrinol. (1999) 140:2581-2591.
Cowley, et al., “Estrogen receptors alpha and beta form heterodimers on DNA,” J. Biol. Chem. (1997) 272:19858-19862.
McDonnell, J.,“Selective estrogen receptor modulators (SERMs): a first step in the development of perfect hormone replacement therapy regimen,” Soc. Gynecolog. Invest. (2000) 7:S10-S15.
Goldstein, “A pharmacological review of selective oestrogen receptor modulators,” Human Reproduction Update (2000) 6:212-224.
Pike, et al., “Structure of the ligand-binding domain of oestrogen receptor beta presence of a partial agonist and a full antagonist,” EMBO J. (1999) 18:4608-4618.
Shiau, et al., “The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen,” Cell (1998) 95:927-937.
Ogawa, et al., “The complete primary structure of human estrogen receptor beta (hER-beta) and its heterodimerization with ER alpha in vivo and in vitro,” Biochem. Biophys. Res. Comm. (1998) 243:122-126.
Paige, et al., “Estrogen receptor (ER) modulators each induce distinct conformational changes in ER alpha and ER beta,” Proc. Natl. Acad. Sci. USA (1999) 96:3999-4004.
Schwarz, et al.,Tetrahedron, 1994, vol. 50, 10709-10720.
Harnik, M.,Israel Journal of Chemistry, 1965, vol. 3, 183-192.
Megati Sreenivasulu
Mohan Arthur G.
Potoski John
Raveendranath Panolil
Vid Galina
Davis Zinna N
Pepper Hamilton LLP
Wyeth
LandOfFree
Preparation of 6-hydroxyequilenins does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Preparation of 6-hydroxyequilenins, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Preparation of 6-hydroxyequilenins will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4115137